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Abstract
Background: Because of the unexpected and often dramatic inhibition of luteinizing
hormone (LH) secretion related with the usage of gonadotropin-releasing hormone
(GnRH)-antagonist, there has been a probable need for exogenous LH supplemen-
tation. There is a basic and clinical evidences that show late development of follicle
needs an LH but there is a threshold for LH requirements during folliculogenesis.
Objective: The purpose of this study was to evaluate the changes in serum LH and the
identification of patients who benefit from the addition of LH.
Materials and Methods: Seventy volunteers for antagonist protocol in IVF cycle
were enrolled in this prospective cross-sectional study. The study was carried out in
Reproductive Health Research Center, University of Medical Sciences between July
2016 and February 2016. Serum LH level was estimated 24 h before and after the first
(GnRH) antagonist injection. The primary outcome was the serum level of LH and its
change in the three groups and the secondary outcome was Egg and Embryo quality.
Results: LH changes above or below 50% had no effect on the number of follicle, the
number of oocyte, Germinal vesicle oocyte, metaphase 1 oocyte, metaphase 2 oocyte,
endometrial thickness, and chemical and clinical pregnancy.
Conclusion:We evaluated the changes of serum LH in the patients who were entered
in the antagonist protocol. Our study showed no significant difference in LH levels 24
h before and after the injection of the antagonist between the three groups, and LH
changes did not affect the outcome of pregnancy.
Key words: Gonadotropin-releasing hormone-antagonist, Luteinizing hormone, In
vitro fertilization.
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1. Introduction
According to the two-cell-gonadotropin hypoth-
esis, androgen plays a crucial role in making
of estradiol (E2) by granulosa cell. Luteinizing
hormone (LH) directly contributes to the control
of granulosa cell function (1). The role of LH in
folliculogenesis includes stimulation of theca cell,
androgen production, triggering ovulation, sup-
porting the corpus luteum, and development of late
follicular stage (2). There is a basic and clinical
evidence that show late development of follicle
needs an LH, but there is a threshold for LH
requirements during folliculogenesis (1). It is known
that < 1% of LH receptor needs to be occupied
to provoke a best steroidogenic response (3), thus
resting level of LH (1–10 IU/L) must be adequate to
offer maximal stimulation to theca cell (3).
The role of in vitro fertilization was accepted
as an effective way for the treatment of infertile
patients (4). It has been well-known that sup-
pressing the release of a pituitary follicle stimu-
latory hormone (FSH) and LH in controlled ovar-
ian hyper stimulation cycles with Gonadotropin-
releasing hormone (GnRH) analogs is an important
factor relevant to the success of IVF treatment.
In some IVF cycle, premature surge was a big
problem. This problem was solved by Schally
in 1971 through introduction of a GnRH agonist
(5). Although GnRH-agonist managed premature
LH surge, it was associated with creating new
problems such as occurrence of cyst formation
at the start of induction ovulation and ovarian
hyper stimulation syndrome (OHSS) (1). The use
of GnRH agonist associated with long duration of
administration, low E2 level and side effect due to
estrogen deficiency (1). Despite the availability of
GnRH antagonist, it was not used for this purpose
due to allergies in 1971 (6). In the antagonist
protocol, several important advantages may be
noted which include the following: in the polycystic
ovarian syndrome (PCOS) patients, GnRH agonist
can be used as a trigger in this protocol and reduce
the risk of OHSS (7, 8). Several studies compared
this two analog and the use of GnRH-antagonist
was associated with shorter stimulation period and
decreased the occurrence of OHSS by more than
50% (9, 10). One of the problems with taking GnRH
antagonist seems to be a reduction in the blood
level of LH.
There is a wide range of pituitary responses to
GnRH antagonists. In some patients that received
a single dose of GnRH-antagonist (3 mg), LH level
may be decreased below a threshold level (9, 11).
Some studies showed that the fast response to
all doses of GnRH antagonists cause a drop in
LH levels, which is similar in among all doses.
However, a large change in LH levels is detected
for the pituitary recovery 24 hr later. While, 24
hr after injection the low antagonist doses allow
a quick recovery and high doses result are a
partial recovery in pre-treatment LH levels (12).
Maximum patients have a normal response; how-
ever, “hypo responders” might ovulate prema-
turely, while “over-suppressed” patients may have
impaired follicular development (12).
Therefore, the aim of this study is the evaluation
of LH change in antagonist protocol and identify
patients who benefit from adding LH.
2. Materials and Methods
In this prospective cross-sectional study, 70 vol-
unteers for antagonist protocol in IVF cycle (due to
PCOS, a poor responder in the previous cycle and
Egg donor) who were referred to the Reproductive
Health Research Center, Tehran University of Medi-
cal Sciences between July 2016 and February 2016
were enrolled. PCOS defined by Rotterdam criteria:
clinical and/or biochemical hyperandrogenism and
oligo-amenorrhea and/or ultrasonographic criteria
≥ 12 follicles (2–9 mm diameter) and/or ovarian
volume ≥ 10 mL (1). Based on ESHRE meeting the
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poor responder patients are defined according to
two criteria of the following criteria:
I. Advanced maternal age (≥ 40 y) or any other
risk factor.
II. A previous POR (cycles canceled or ≤ 3
oocytes with a conventional protocol).
III. An abnormal ovarian reserve test (antral fol-
licle count < 5–7 follicles or anti-Mullerian
hormone (AMH) < 0.5–1.1 ng/ml) (13).
Exclusion criteria was allergy to antagonist and
patients with long agonist protocol. On the first
day of menstrual cycle, suppression of ovary
was confirmed by ultrasonography. The hormonal
assessment was performed on the 2nd day of
menstrual cycle including FSH, LH, and E2. For
all patients gonadotropin (Follistim, Merck; Gonal-
F, EMD-Serono) was started from the 2nd day of
menstruation according to AMH and antral follicular
countage, previous response to gonadotropin. Six
days after the start of gonadotropin, ultrasonog-
raphy was performed for estimate follicular size
and repeated if necessary. When follicle reached
≥ 13 mm, we used GnRH-antagonist (Cetrotide,
EMD-Serono 0.25 mg/day SC). Serum LH level was
estimated 24 hr before and after first Cetrotide
injection. When two follicles were < 18 mm, we
used Human chorionic gonadotropin (10.000 IU;
Pregnyl, Organon, Oss, Netherlands) intramuscular
as a trigger; 36 hr after trigger, oocyte retrieval
was performed under ultrasound guide. Primary
outcome was the serum level of LH and its change
in the three groups and the secondary outcome
was Egg and Embryo quality.
2.1. Ethical consideration
The study was approved by the Ethics Com-
mittee Review Board of Tehran University (No:
IRTUMS.VCR.REC.1395.1405). Written inform con-
sent was obtained from all participants.
2.2. Statistical analysis
The data were analyzed using Statistical Pack-
age for the Social Sciences, version 20, SPSS
Inc, Chicago, Illinois, USA (SPSS) software. Inde-
pendent t-test, Man–Whitney test, and Kruskal–
Wallis was used to compare the parametric and
nonparametric parameters between groups. Com-
parison of qualitative variables between groups
was performed using Chi-square test. The quanti-
tative parameters were reported as mean ± SEM.
A p < 0.05 was taken as statistically significant.
Spearman correlation test was used to assess the
correlation of LH parameters with other factors.
3. Results
Table I shows the demographic characteristics
and basal Hormonal assay. As expected, the aver-
age age of the poor responder group is more
than two other groups (37.8 ± 4.43) (p = 0.001).
According to Kruskal–Wallis (nonparametric test),
the serum level of basal LH that was measured on
the second day of menstruation shows significant
difference (p = 0.004). As expected serum level of
LH is higher in PCOS (6.7 ± 4.3) than poor respon-
der (5.18 ± 3) and normal responder groups (3.67
± 4) (Figure 1). As well as the level of AMH is high
in PCOS groups. Other variables examined (basal
FSH, E2, BMI, duration of infertility, number of
previous IVF) in three groups showed no significant
difference. Results of Table II show the significant
differences between the three groups containing
follicle-number, oocyte number, metaphase 2 (M2)
oocyte, Germinal vesicle (GV) oocyte, number of
transferred embryos and the number of consumed
Gonadotropin ampule. To determine the difference
between the three groups, we used Post Hoc and
Bonferroni test. The number of follicles, GV oocyte
and transferred embryo show significant difference
between the PCO and poor responder group and
the PCO and normal responder only, but there was
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no difference between Poor and normal responder.
The number of the eggs and M2 oocyte has only
significant difference between the PCO and Poor
responder patients. This difference cannot be seen
in each other. But it was significantly different
between the three groups together in the number
of gonadotropins ampule, and gonadotropin con-
sumed in poor responder group was more than
other groups (p = 0.0001). There was no significant
difference (p = 0.45, p = 0.843) in LH levels 24
h before and after the injection of the antagonist
between the three groups. As well as, the LH ratio
and LH change not differ in the three groups (p
= 0.077, p = 0.486). According to the Chi-square
test, the LH difference percent in the three groups
was not significant (p = 0.81). Spearman correlation
test was used to assess the correlation of LH
parameters with the number of follicle and oocyte
and GV oocyte, metaphase 1 (M1) oocyte, M2
oocyte, endometrial thickness. The only significant
relationship was seen between LH ratio and M1
(r = 0.31, p = 0.008) and LH change and M1(r =
0.26, p = 0.025). In other words, if the LH (24 hours
after administration of the antagonist) is high, that
is, the LH suppression by the antagonist is lower
and the rate of M1 oocyte was more. According to
Mann–Whitney and Fisher test, the correlation of
the LH decrease were not significantly associated
with GV, M1, M2 oocyte, the number of the follicle,
the number of the oocyte, endometrial thickness
(Table III). In the other words, the lower levels of LH
after the injection had no effect on outcomes.
Table I: Characteristics of patients.








Age (y) 37.8 ± 4.43 30.73 ± 4.82 32.55 ± 5.84 0.001
BMI (kg/m2) 27.23 ± 3.02 25.65 ± 3.65 25.63 ± 2.25 0.43
infertility Duration (y) 6.35 ± 4 6.08 ± 5.04 4.67 ± 4.56 0.46
FSH (Iu/ml) 7.4 ± 3.1 6.56 ± 6.45 6.07 ± 2.80 0.08
LH base (Iu/ml) 5.18 ± 3 6.7 ± 4.3 3.67 ± 1.35 0.004
E2 41.15 ± 16.4 41.73 ± 7.2 41.7 ± 15.2 0.08
AMH 0.98 ± 0.97 8.7 ± 5.16 2.8 ± 1.4 0.001
TSH 3.11 ± 2.48 2.45 ± 1.14 2.29 ± 1.16 0.60
ViT D 22.11 ± 13.13 18.16 ± 14.09 19.75 ± 12.52 0.29
Number of previous IVF (N, %) 0.21 ± 0.53 0.17 ± 0.38 0.18 ± 0.39 0.96
Note: Data presented as mean ± SD; these parameters were analyzed with Kruskal-Wallis (nonparametric)
BMI: Body mass index FSH: Follicle stimulating hormone LH: Luteinized Hormone
E2: Estradiol AMH: Anti Mullerian Hormone TSH: Thyroid Stimulating Hormone
ViT D: Vitamin D IVF: in vitro fertilization Group1: Poor responder
Group2: PCOS Group3: Normal responder
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Table II: Treatment outcomes in a patient in three groups.








LH (24 hr before antagonist)* 3.2 ± 3.89 4.1 ± 4.8 3.11 ± 1.60 0.45
LH(24 hr after antagonist)* 2.68 ± 1.83 2.55 ± 1.10 2.64 ± 1.42 0.843
LH ratio* 1.67 ± 2.3 0.89 ± 0.42 0.89 ± 0.44 0.077
LH change* –0.55 ± 3.6 –1.5 ± 4.8 –0.47 ± 1.14 0.486
LH decrease* 0.67 ± 2.3 –0.11 ± 0.42 –0.10 ± 0.44 0.077
No. follicles * 4.45 ± 3.2 17.43 ± 7.62 7.66 ± 3.9 0.001
No. Oocyte* 2.8 ± 2.58 12.08 ± 5.96 5.11 ± 3.29 0.001
Quality oocyte*
M1 0.35 ± 0.58 0.69 ± 1.1 0.29 ± 0.66 0.494
M2 0.35 ± 0.58 9.7 ± 6.2 4.44 ± 2.96 0.001
GV 0.2 ± 0.41 1.06 ± 2.16 0.37 ± 1.0 0.004
Endometrial thickness (mm)* 7.5 ± 1.7 7.5 ± 1.3 7.64 ± 1.5 0.839
Days of Stimulation* 10.15 ± 2.8 10.8 ± 4.3 9.7 ± 2.4 0.578
Number of Gonadotropin* 4 ± 0 2.26 ± 0.61 3.25 ± 0.85 0.0001
Cycle cancelation ** 0.153
Yes 7 (35%) 10 (43.5%) 5 (18.5%)
NO 13 (65%) 13 (56.5%) 22 (81.5%)
Total number of embryo* 1.4 8 ± 5.4 2.37 ± 2.3 0.001
Embryo transfer** 0.099
Yes 8 (42) 4 (17.5) 12 (44.5)
No 11 (58) 19 (82.5) 15 (55.5)
Embryo quality*
Lower than 8 cell 6 (66.7) 22 (95.7) 16 (80) 0.09
8 cell 4 (44) 15 (65.2) 13 (65) 0.51
Morolla 0 0 3 (5.8) 0.07
Blastocyst 0 1 (4.3) 0 0.68
LH decrease**
> 50% 5 (26) 3 (13) 1 (4) 0.081
< 50% 14 (74) 20 (87) 26 (96)
Note: *data presented asmean± SD and these parameters were analyzedwith Kruskal–Wallis (nonparametric
**data presented as n(%), and these parameters were analyzed with Fisher’s exact test or Chi-square Test
LH: Luteinized Hormone M1: Metaphase 1 M2: Metaphase 2
GV: Germinal vesicle LH change: LH after antagonist- LH before the antagonist
LH ratio: LH after antagonist/LH before antagonist Group1: Poor responder
Group2: PCOS Group3: normal responder
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Table III: Correlation of LH decreases percent with treatment outcome in total group.
Treatment Group > 50% (n = 14) < 50% (n = 23) p-value
Variables
M1 0.21 ± 0.42 0.50 ± 0.94 0.39
M2 4.07 ± 4.35 5.24 ± 5 0.11
GV 1.2 ± 2.1 0.61 ± 1.32 0.30
Oocyte number 5.4 ± 5.8 7.2 ± 5.6 0.13
Endometrial thickness (mm) 7.6 ± 1.9 7.6 ± 1.2 0.99
Total number of the embryo 2.8 ± 3.6 4.1 ± 4.7 0.28
Note: Data presented as mean ± SD. Data analyzed with Mann-Whitney test (nonparametric)
M1: Metaphase 1 M2: Metaphase 2 GV: Germinal vesicle
Figure 1: Slope or shot in the PCO is significantly higher than the other two groups, except in accordance with the above figure
are more tangible between PCO and Normal.
4. Discussion
We evaluate the changes of serum LH in the
three groups of patients who were entered in
antagonist protocol. In none of the patients in the
three groups, the blood level of the LH followed
the GnRH antagonist reached below one. There
was no reduction in more than 50% of the LH
levels in any group following a GnRH antagonist.
In our study, there was no significant difference
in the LH levels 24 h before and after injection of
the antagonist between three groups, as well as
on the LH ratio we didn’t find a significant differ-
ence. Changes in LH more than 50% (drop more
than 50% or even increase) was not significantly
associated with GV, M1, M2 oocyte, the number of
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the follicle, the number of the oocyte, endometrial
thickness. Several studies have evaluated the role
of LH in antagonist protocol (14). Studies in hypog-
onadotropic patients using r-FSH established that
FSH can induce follicular development in the
preovulatory phase, but E2 and androstenedione
remain very low, and this advocates that follicular
development depends on the action of LH to
induce androgen biosynthesis as a substrate for
aromatase activity (15). Suitable folliculogenesis
and steroid genesis are necessary for successful
fertilization and implantation. Therefore, it depends
upon a certain threshold level of LH. Although, the
amount of LH necessary for standard follicle and
oocyte maturation is not known (16), it is likely to be
very low since a best steroidogenic response can
be prompted when < 1% of follicular LH receptors
are occupied (16). There is also evidence that
excessive level of LH can have an adverse effect
on follicular development (17). So, there is a window
for LH while the low and high level of LH is a
harmful effect in follicular maturation (18). This is
an update of a Cochrane review in 2001, and
previously updated in 2006 and 2011 (19). In the
study by Huirne and coworkers, they evaluated the
change of plasma level in LH in five groups with
different dosage of GnRH–antagonist, and effect
of these changes on IVF outcome. In this study,
no pregnancies were observed in relation to either
very high or low LH which protects the window
hypothesis (20). According to this study, excessive
fluctuation in LH levels might disrupt this balance
and associate with adverse effect (20). Overall it
seems that LH may have a valuable effect through
a mechanism that recovers oocyte maturation (20).
In the studies by Gomez–Palomares and coworkers
(1) and Lisi and coworker, significant improvement in
IVF outcome in poor responder patients was found
(21). Because of the unexpected and often dramatic
inhibition of LH secretion related with the usage
of GnRH-anta, there has been a probable need
for exogenous LH supplementation (1). The meta
analysis from six clinical randomized trials showed
that normogomadotropic patients did not benefit
from adding LH (22). In the cohort retrospective
study in poor responder or AMA (advanced mater-
nal age) did not protect add LH supplementation
(22). In the study by Hill and coworkers, adding
exogenous LH in AMA patients improved implan-
tation and pregnancy rate (23). In the study by
Kol, patients who were hyper sensitive to GnRH–
antagonist benefitted from r-LH (12). In the study by
Younis and coworkers, r-LH supplementation to r-
FSH following GnRH-antagonist administration did
not seem to significantly increase serum E2 level
on the day of Human chorionic gonadotropin
administration in AMA patients. This recommends
that endogenous serum LH levels following GnRH-
antagonist beginning are adequate for suitable
late follicular ovarian steroidogenesis (14). The
novelty of our study is evaluating the LH change in
three subgroups including hyper responder (PCOS
patients), hypo responds (poor ovarian reserve),
and normal responder (donor patients).
Limitation
Limitations of the study:
1. Small sample sizemay affect results; however,
further clinical trial studies with large sample
size are needed.
2. Because in some patients we had frozen
embryos, there was no possibility of assess-
ing pregnancy.
5. Conclusion
The results showed no difference in the levels
of LH and changes of LH in antagonist protocol
between three groups, so it is not practical to
assess the LH level in ART cycles.
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